This evaluation was discussed by the HST evaluation committee on Wednesday 12 June 2024.
Following the committee meeting, this evaluation will be paused while additional analyses are provided by the company.
The reason the committee asked for this is because it wanted to know further information and see clinical and cost-effectiveness analyses:
• exploring clear starting and stopping rule(s) for patients. This was discussed during the committee meeting, and the committee would like to understand in whom, and when, the treatment is most effective and cost-effective.
• Other modelling issues.
We expect to hold a second committee meeting on 5 September 2024 to consider the additional analyses from the company. The publication timelines will also change to align with this committee meeting date. We will confirm the timelines this on the website and let participating stakeholders know by August 2024.